Pharmaceutical major Lupin Limited has acquired Nanomi B.V. in the Netherlands. Financial details of the buyout have not yet been disclosed.
With this acquisition, Lupin would be able to manufacture complex injectables with innovative drug delivery systems.
Nanomi, the Dutch life sciences company, provides advanced drug delivery products, enabled by its monosphere technology. The company, founded in 2004, has expertise in drug delivery, molecular imaging and diagnostics.
Also Read
Nanomi has patented technology platforms to develop complex injectable products. It has a rich talent pool of scientists who would be backed by Lupin’s global R&D and manufacturing teams, said a Lupin statement.
Vinita Gupta, Chief Executive Officer, Lupin Limited said “We are very pleased with the acquisition of Nanomi. With the use of Nanomi’s proprietary technology platform, Lupin would be able to make significant inroads into the niche area of complex injectables.”
ALSO Read: Focus on pharmaceutical M&As back after Lupin negotiation buzz


